Stratulat, Albulescu si Asociatii, Baker McKenzie assisted Rohatyn in the deal, while Tuca, Zbarcea si Asociatii assisted Amethyst.
“Amethyst is in a position to address the growing need for cancer care in Europe, which is on the rise due to lifestyle trends and the aging population, said Colin Clark, Rohatyn’s Head of CEEMEA Private Markets Investing, in a release on the corporate website.
Amethyst specializes in cancer care for patients in Europe and provides radiation therapy, medical imaging services, as well as clinical studies on the local market.
Rohatyn plans to speed up Amethyst’s growth in Europe through new greenfield clinics and partnerships with hospitals. The asset management firm is not at its first acquisition in Romania, having bought pet supplies retail chain Animax last year, which had 80 stores.
“The investment, in terms of both capital and expertise expanding corporate footprints, expediates a new phase in the development of Amethyst,” Ludovic Robert, co-founder of Amethyst, commented.
Amethyst has nine clinics in Europe, two of which in Romania (Bucharest and Cluj) and the rest in Poland, Italy, France and Austria.
(English version by Loredana Fratila-Cristescu)